



HAL
open science

Fanconi anemia A protein participates in nucleolar homeostasis maintenance and ribosome biogenesis

Anna Gueiderikh, Frédérique Maczkowiak-Chartois, Guillaume Rouvet, Sylvie Souquère-Besse, Sébastien Apcher, Jean-Jacques Diaz, Filippo Rosselli

► To cite this version:

Anna Gueiderikh, Frédérique Maczkowiak-Chartois, Guillaume Rouvet, Sylvie Souquère-Besse, Sébastien Apcher, et al. Fanconi anemia A protein participates in nucleolar homeostasis maintenance and ribosome biogenesis. *Science Advances*, 2021, 7 (1), 10.1126/sciadv.abb5414 . hal-03376729

HAL Id: hal-03376729

<https://cnrs.hal.science/hal-03376729>

Submitted on 20 Oct 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

CELL BIOLOGY

Fanconi anemia A protein participates in nucleolar homeostasis maintenance and ribosome biogenesis

Anna Gueiderikh^{1,2,3}, Frédérique Maczkowiak-Chartois^{1,2,3}, Guillaume Rouvet^{1,2,3},
Sylvie Souquère-Besse^{2,3,4}, Sébastien Apcher^{2,3,5}, Jean-Jacques Diaz⁶, Filippo Rosselli^{1,2,3*}

Fanconi anemia (FA), the most common inherited bone marrow failure and leukemia predisposition syndrome, is generally attributed to alterations in DNA damage responses due to the loss of function of the DNA repair and replication rescue activities of the FANCA pathway. Here, we report that FANCA deficiency, whose inactivation has been identified in two-thirds of FA patients, is associated with nucleolar homeostasis loss, mislocalization of key nucleolar proteins, including nucleolin (NCL) and nucleophosmin 1 (NPM1), as well as alterations in ribosome biogenesis and protein synthesis. FANCA coimmunoprecipitates with NCL and NPM1 in a FANCCore complex-independent manner and, unique among the FANCCore complex proteins, associates with ribosomal subunits, influencing the stoichiometry of the translational machineries. In conclusion, we have identified unexpected nucleolar and translational consequences specifically associated with FANCA deficiency that appears to be involved in both DNA damage and nucleolar stress responses, challenging current hypothesis on FA pathophysiology.

INTRODUCTION

The nucleolus is a dynamic, membrane-less nuclear substructure visible in interphase that disappears at the onset of mitosis to reappear at the end of telophase. Several hundred proteins are hosted inside the nucleolus together with the genomic sites containing the ribosomal DNA (rDNA) sequences organized in tandemly repeated clusters dispersed on the five human acrocentric chromosomes. Three major events occur in the nucleolus: the RNAPolII-mediated synthesis of the 45S/47S ribosomal RNA (rRNA) precursors and their processing to generate the 28S, 18S, and 5.8S rRNA molecules that will be assembled with the ribosomal proteins (RPs) to form the pre-ribosomes, which are successively processed to form the cytosolic 40S and 60S ribosome subunit. In addition to its canonical role in the biogenesis of the ribosome, the nucleolus acts as a sensor and transducer of cellular stress originating from the nucleolus itself, the nucleus, or the cytosol. It can quickly lose homeostasis by modifying its activity, size, shape, and protein content to adapt cell metabolism to threatening events. The stress-associated transitory loss of nucleolar homeostasis or the nucleolar stress response (NSR), even in the absence of DNA damage and its signaling, is associated with the activation of the p53-p21 axis to restrain cellular proliferation and allow time to recover from stress (1, 2).

The unrestrained activation of the p53-p21 axis has been associated with hematopoietic stem cell (HSC) attrition that characterizes inherited bone marrow failure (iBMF) syndromes, including dyskeratosis congenita (DC), Shwachman-Diamond syndrome (SDS), Diamond-Blackfan anemia (DBA), and Fanconi anemia (FA), the most frequent and genetically heterogeneous iBMF syndrome. In contrast to DC, SDS, and DBA, in which BMF and p53-p21 activation rely on abnormalities in nucleolar homeostasis and/or ribosome biogenesis

(3, 4), FA is attributed to abnormalities in the DNA damage response (DDR) (5–7) that lead to p53-p21 activation and BMF (8, 9). The canonical function attributed to the molecular pathway defined by FA proteins (FANCA) is to cope with DNA interstrand cross-links (ICLs) and stalled replication forks that can arise from endogenous aldehyde metabolism or following exposure to ICL-inducing agents, such as mitomycin C, cisplatin, or photoactivated psoralens (5–7, 10, 11). The FANCA pathway is organized into three distinct functional groups. The FANCCore complex, which comprises FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, FAAP20, and FAAP100, is assembled to monoubiquitinate the FANCD2-FANCI (ID2) heterodimer, allowing its accumulation in subnuclear foci required for the optimal work of the third group of FANCA proteins, which includes nucleases and homologous recombination proteins (5–7). Among the more than 20 genes involved in FA, FANCA biallelic inactivating mutations account for more than 60% of FA cases worldwide (5–7). However, FANCA is dispensable for optimal FANCD2/FANCI monoubiquitination (12), and several BMF-associated mutations of FANCA do not lead to DNA damage hypersensitivity (13–15), suggesting that FANCA affects BM homeostasis by also participating in pathways other than the DNA repair network. Beyond the DNA repair/DDR, the FANCA pathway has been associated with several other cellular and systemic biological activities (16), including proinflammatory cytokine production and responses (17–20), transcription (21–23), mRNA splicing (24), and reactive oxygen species metabolism (25–27), and its failure extends further than BMF to developmental abnormalities, cancer predisposition, and chromosomal instability.

Here, we investigated nucleolar protein localization, rDNA stability, and transcription as well as translational activity in FA-deficient cells. We demonstrated a specific involvement of FANCA in nucleolar homeostasis, ribosome biogenesis, and translation beyond some nucleolar abnormalities likely associated with the DNA repair defect associated with FANCA pathway loss of function. Our observations possibly account for the high frequency of FA patients with inactivating mutations in FANCA and for the BMF in FANCA-mutated patients with normal resistance to DNA damage injury (13–15).

¹CNRS—UMR9019, Équipe labellisée “La Ligue contre le Cancer,” 94805 Villejuif, France. ²Gustave Roussy Cancer Center, 94805 Villejuif, France. ³Université Paris-Saclay—Paris Sud, Orsay, France. ⁴CNRS—UMS3655, 94805 Villejuif, France. ⁵INSERM—UMR1015, 94805 Villejuif, France. ⁶Université Lyon, Université Claude Bernard Lyon 1, Inserm 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, 69373 Lyon cedex 08, France.

*Corresponding author. Email: filippo.rosselli@gustaveroussy.fr

RESULTS

FANCA deficiency is associated with nucleolar protein mislocalization

Nucleolar status was monitored looking at the subcellular distribution of key nucleolar proteins such as fibrillarlin (FBL), nucleolin (NCL), upstream-binding nucleolar transcription factor 1 (UBF), and nucleophosmin (NPM1 or B23). More than 70% of FANCA pathway-proficient HeLa or U2OS cells harbored nucleoli with irregular borders delimited by a thick ring of NCL or NPM1, inside which FBL and UBF were distributed in a fairly homogeneous way (Fig. 1, A to D, and fig. S1, A to C). In contrast, 48 to 96 hours after the small interfering RNA (siRNA)-mediated depletion of FANCA, less than 30% of cells had nucleoli with the previously described distribution of NCL, NPM1, FBL, UBF, and/or irregular borders (Fig. 1, A to D, and fig. S1, A to C). In more than 70% of the FANCA-depleted cells, nucleoli took either a more round and regular shape delimited by an extremely faint ring of NCL or they appeared “empty” with the proteins displaced out of the nucleolus or eventually accumulating in nucleolar peripheral structures called “caps” (Fig. 1, A to D, and fig. S1, A to C). siRNA-mediated depletion of FANCA did not affect the expression of the analyzed nucleolar proteins (fig. S1D) or the number of nucleoli per cell (fig. S1E), and we separately tested the three previously pooled FANCA siRNA sequences with similar results (fig. S1F). Electronic microscopy (EM) analysis supported the occurrence of less organized and/or more condensed and rounded nucleoli in FANCA-depleted cells (Fig. 1E). Compared to the depletion of FANCA, down-regulation of FANCC, belonging as FANCA to the FANCCore complex, FANCG, a direct interactor of FANCA, or FANCD2, a FANCCore complex target, had reduced but still significant consequences on the frequency of cells with nucleolar abnormalities when compared to the FANCA pathway-proficient cells (Fig. 1F and fig. S1, C, G, and H). However, whereas the depletion of FANCC, FANCG, or FANCD2 led to a similar frequency of cells with nucleolar abnormalities, this level was significantly lower than that observed when FANCA was depleted (Fig. 1F and fig. S1, G and H). The concomitant down-regulation of FANCA with FANCC, FANCG, or FANCD2 did not modify the frequency of cells with nucleolar abnormalities observed when only FANCA was depleted.

Next, we extended our observations to human primary and SV-40 immortalized fibroblasts. In FANCA pathway-proficient primary fibroblasts, the frequency of cells with a noncanonical nucleolar distribution of NCL and/or FBL ranged between approximately 5 and 18% (Fig. 1G). With respect to the mean value of the FANCA pathway-proficient cells (12%; red dotted line in Fig. 1G), all analyzed FANCA-mutated primary fibroblasts presented a significant, albeit variable, increase in the frequency of cells with altered nucleoli, a frequency that was invariably reduced by the ectopic expression of the wild-type (WT) FANCA gene (Fig. 1, G and H). Frameshift and/or nonsynonymous mutations compromising the C-terminal part of FANCA were identified in FANCA primary fibroblasts (table S1), and FANCA protein in primary fibroblasts was hardly detectable by Western blot (WB) (fig. S1I). Thus, even if we cannot exclude that the observed variability in the frequency of cells with nucleolar abnormalities may be linked to the different mutations affecting FANCA or the residual expression level of mutated proteins, it could be due to other characteristics specific to each cell line or to their different adaptation to the culture conditions. The WT cell lines also exhibit substantial variations in the frequency of cells with nucleolar abnormalities that are proportionally similar to those of FANCA-deficient cells




Fig. 1. Nucleolar abnormalities in FANCA pathway-deficient cells. (A and C) Wide fields and single nuclei of HeLa (A) or U2OS (C) cells transfected with the indicated siRNAs and stained with anti-NCL (red) and anti-FBL (green) antibodies. DAPI (4',6-diamidino-2-phenylindole) staining visualizes nuclei. (B and D) Percentage of HeLa (B) or U2OS (D) cells with canonical nucleoli (irregular shape) or a round or cap-like shape. The mean of six (B) or three (D) independent experiments ± SEM is reported. NS, not significant. (E) Electronic micrographs showing nucleoli as observed in the majority of HeLa cells (i) and the disorganized/condensed nucleoli observed after FANCA depletion (ii and iii). (F) Percentage of HeLa cells ± SEM with altered nucleoli 72 hours following transfection with untargeted (n = 6) (siLacZ) or FANCA-targeted (n = 6), FANCC-targeted (n = 4), FANCG-targeted (n = 3), or FANCD2-targeted (n = 4) siRNA. (G and H) Percentage of cells with altered nucleoli in (G) WT, FANCA^{-/-}, and FANCA-corrected, FANCC^{-/-}, and FANCG^{-/-} primary fibroblasts and in (H) WT, MRC5, FANCC^{-/-} (GMO0449), and FANCG^{-/-} primary fibroblasts (PD352) and their immortalized counterparts (MRC5-SV, GM13136, and GM16335) under basal conditions or following FANCA depletion. The dotted red line represents the mean of the five primary WT cells. (I) Percentage of cells with altered nucleoli in HEK293- and HEK293-FlagFANCA-expressing cells before or after siRNA-mediated FANCA and/or FANCG depletion. Bars represent the mean of three to six independent experiments ± SEM. (J and K) Western blots showing the expression of the indicated proteins in HEK293 and HEK293-FlagFANCA cells. Extracts from independent experiments or transfections in the same experiment (bis) are shown. Statistics were assessed with two-tailed unpaired Student's t tests (*P < 0.05, **P < 0.01, and ***P < 0.005).

(i.e., a difference of approximately three times between the lowest and the highest, 4.8% versus 18.4% and 21.7% versus 68.3% in WT and *FANCA*^{-/-} cells, respectively). Compared to the WT, two analyzed *FANCC*^{-/-} primary cell lines were indistinguishable, whereas in both *FANCG*-deficient fibroblasts, the frequency of cells with nucleolar abnormalities was more elevated (Fig. 1G). SV40-mediated immortalization increases the frequency of cells with nucleolar abnormalities regardless of their FANCA pathway status (Fig. 1H). However, immortalized *FANCC*^{-/-} and *FANCG*^{-/-} cell lines demonstrated a significant increase in the frequency of cells with mislocalized nucleolar proteins compared with FANCA pathway-proficient MRC5-SV cells. Moreover, *FANCA* depletion in *FANCC*^{-/-} or *FANCG*^{-/-} immortalized fibroblasts led to an additional increase in cells with nucleolar abnormalities (Fig. 1H). An increased level of nucleolar abnormalities was also observed in primary fibroblasts from *Fanca*^{-/-} mice (fig. S1, J to L).

We observed a high level of nuclear abnormalities in *FANCG*^{-/-} primary cells (Fig. 1G). *FANCG* directly interacts with *FANCA*, forming FAAP20, one of the three subgroups of the FANCCore complex (5–7). Because the depletion of one protein in a complex is expected to affect the level of its partner(s), we decided to analyze the nucleolar consequence of *FANCG* depletion in human embryonic kidney (HEK) 293 cells stably expressing a Flag-tagged *FANCA*, which should maintain a satisfactory level of *FANCA* even in the absence of *FANCG* (Fig. 1, I to K). As in HeLa and U2OS cells (Fig. 1F and fig. S1, G and H), the frequency of cells with altered nucleoli in the parental HEK293 cell line increased following *FANCA* or *FANCG* depletion, with the loss of *FANCA* being more effective than *FANCG* (Fig. 1I). As expected for directly interacting proteins, *FANCA* depletion impinges on *FANCG* stability, reducing its expression, and vice versa, *FANCG* depletion affects *FANCA* expression (Fig. 1J). Notably, when *FANCG* was depleted in the Flag-*FANCA*-overexpressing cells, the level of *FANCA* appeared nearly unaltered (Fig. 1K), and accordingly, the frequency of cells with altered nucleoli was lower compared to the parental HEK293 cell line (Fig. 1I). Thus, it seems that the increased consequences of *FANCG* loss of function clearly observed in some settings (Fig. 1, G and I) but not in others (Fig. 1F) could be due to both FANCA pathway inactivation (as observed in *FANCC*- and *FANCD2*-deficient cells) and the impact of *FANCG* depletion on the expression of its direct partner, *FANCA*.

Overall, our data pinpoint the presence of mislocalized nucleolar proteins in FANCA pathway-deficient cells, mainly in association with *FANCA* (or *FANCA*-*FANCG* heterodimer) loss of function.

Increased nucleolar stress in *FANCA*-deficient cells is independent of DNA damage, ATM/ATR signaling, or accumulation of RNA-DNA hybrids

The FANCA pathway has key roles in DNA repair, replication rescue, and coordinating replication and transcription cellular functions (28). This raises the question of whether the nucleolar abnormalities observed in *FANCA*-deficient cells were an additional consequence of alterations in the previous process, i.e., the outcome of increased rDNA damage or instability, the result of altered DNA damage signaling, and/or the consequence of defective coordination between transcription and replication machineries.

Not surprisingly, in light of their role in genomic stability maintenance, we identified by cell fractionation the presence of FANCA proteins inside the nucleolus (Fig. 2A). The presence of *FANCA* inside the nucleolus was validated by immunofluorescence analysis

of a yellow fluorescent protein (YFP)-*FANCA* construct (Fig. 2B) and that of *FANCD2* by chromatin immunoprecipitation (ChIP) sequencing analysis. Depletion of *FANCA* or *FANCD2* led to a slightly significant ($P < 0.05$) increased frequency of cells with nucleoli presenting γ -H2AX foci, a widely accepted readout of the presence of DNA breaks, in association with the induction of rDNA rearrangements as determined by polymerase chain reaction (PCR) analysis (Fig. 2, C and D). DNA breakage-induced ataxia telangiectasia mutated (ATM) signaling participates in the redistribution of the nucleolar proteins in the nucleoplasm, where some of them, including NCL and NPM1, participate in the DDR (29–33). However, even if ATM signaling is known to be constitutively active in FANCA pathway-deficient cells (34, 35), the inhibition or depletion of ATM and/or of its related kinase, ataxia telangiectasia and Rad3 related (ATR), led only to a slight and not statistically significant reduction in the frequency of *FANCA*-deficient cells with nucleolar abnormalities (Fig. 2E).


Next, as previously published genome wide (36), we observed that the level of the nucleolar RNA-DNA hybrid structures or R-loops, readout of badly managed transcription-replication conflicts, is increased as a consequence of *FANCA* depletion but to a similar extent as observed in *FANCD2*-depleted cells (Fig. 2F).

Overall, the above data validated that siRNA-mediated depletion of *FANCA* recapitulates key cellular features of FA to a similar extent as *FANCD2* depletion, which, in contrast to *FANCA* down-regulation, presents fewer signs of nucleolar abnormalities (Fig. 1F). Thus, although the increased level of DNA damage and/or of its signaling associated with FANCA pathway deficiency can undoubtedly participate in the observed nucleolar abnormalities, the stronger consequences of *FANCA* loss of function on nucleolar protein localization suggest that this protein (or its *FANCA*-*FANCG*-FAAP20 subcomplex) could have additional roles in nucleolar homeostasis maintenance.

Nucleolar stress in *FANCA*-depleted cells delays rDNA transcription


As the production of rRNAs is one of the main nucleolar activities, we asked whether the observed abnormalities in nucleolar protein localization could be a cause or consequence of abnormalities in rDNA transcription. Pulse-chase experiments with [³²P]orthophosphate followed by electrophoretic separation of the pre-rRNA species (Fig. 3B and fig. S2A, left) or Northern blot analysis (Fig. 3C) revealed some anomalies in rDNA transcription/processing in *FANCA* down-regulated cells. The 45S/47S rRNA precursors are produced at a reduced rate in *FANCA*-deficient relative to FANCA pathway-proficient cells, and their processing, qualitatively unaltered, is slowed down in the absence of *FANCA*. Thus, at steady state, a consequent increased level of both 45S/47S and 30S rRNA precursors is observed (Fig. 3B and fig. S2A), suggesting a delay in pre-rRNA transcription/processing that appears unchanged in *FANCD2*-depleted cells (fig. S2A, right). Last, nascent RNA synthesis was also evaluated by the quantification of the incorporation of the modified RNA precursor 5-ethynyl uridine (EU) (37). However, fluorescence-activated cell sorting (FACS) analysis of EU incorporation showed a marginal, if any, increase in *FANCA*-depleted cells, probably due to the confounding incorporation of EU in all cell transcripts (fig. S2B).

ChIP-quantitative PCR (qPCR) analysis demonstrated that *FANCA* depletion leads to a lower association of RNAPolII in the rDNA promoter region (H42.9 and H1) in parallel with its increased accumulation on the terminal part of the rRNA coding region (H8)



(Fig. 3, A and D). Accordingly, we also observed a reduced level of the transcription-activating H3K4me3 histone mark on the promoter region. Last, immunofluorescence analysis revealed that the level of nucleolar G4s, which are secondary DNA structures that facilitate

transcription progression (38–42) and that are regulated by NCL and NPM1, was lower in FANCA-deficient than in FANCC pathway-proficient or FANCD2-deficient cells (Fig. 3, E and F).



transcription progression (38–42) and that are regulated by NCL and NPM1, was lower in FANCA-deficient than in FANCC pathway-proficient or FANCD2-deficient cells (Fig. 3, E and F).

Together, our data are consistent with the presence of some perturbations in rDNA transcription in FANCA-depleted cells, associated with an increased level of R-loops (Fig. 2F) and a lower level of G4s (Fig. 3E), which cooperatively may slow RNAPolI progression.

However, their limited magnitude suggests that they are more likely a consequence of FANCA depletion–associated loss of the nucleolar proteins and not a cause of it.

FANCA coimmunoprecipitates with NPM1 and NCL

The consequence of FANCA loss of function on nucleolar protein localization seems to be due to a still-undetermined role of the protein in cell physiology and not an additional consequence of its loss of function in DNA processes such as DNA repair, replication, recombination, and/or transcription.

To shed light on this role, we performed FANCA immunoprecipitation by using three different antibodies directed against different epitopes of FANCA in protein extracts isolated from HSC93, U2OS, or HEK293 cells (Fig. 4A). The three antibodies successfully coimmunoprecipitated FANCA with its well-known partner FANCG. Conversely, FANCA was identified among the FANCG-associated proteins (Fig. 4B). Successively, we examined the presence of NPM1 and NCL in FANCA- and FANCG-immunoprecipitated cell extracts. Both nucleolar proteins were undoubtedly and repeatedly retrieved in FANCA but not in FANCG immunoprecipitations (Fig. 4, A and B). A yeast two-hybrid screen with FANCA as bait retrieved FANCG and FAAP20, its two key direct interactors, but failed to identify NPM1 or NCL among its potential partners. Thus, still unidentified proteins or RNAs could mediate the observed FANCA-NCL-NPM1 coimmunoprecipitation. Treatment of the immunoprecipitated protein complexes with benzonase, a DNA/RNA dual-specific nuclease, affected the immunoprecipitation of NCL but had minor consequences on FANCA-NPM1 and FANCA-FANCG coimmunoprecipitation (Fig. 4C). Thus, at least part of the FANCA-NCL coimmunoprecipitation might depend on RNA, for which FANCA has high affinity (43). Moreover, whereas the coimmunoprecipitation between FANCA and FANCG was maintained at a higher salt concentration (300 mM), NPM1 and NCL were no longer found in association with FANCA in such a setting (Fig. 4D). Last, we immunoprecipitated FANCA with NCL/NPM1 in both *FANCG*- and *FANCC*-mutated lymphoblasts, suggesting that FANCA pathway loss had no major impact on the coimmunoprecipitation between FANCA and NCL and NPM1 (Fig. 4E and fig. S3A). Next, we tried the reverse, i.e., coimmunoprecipitated FANCA with antibodies directed against NPM1 or NCL. In both cases, even loading on the gel two times more immunoprecipitated proteins than for the previous analysis, it appeared very hard to detect the presence of FANCA, if any, in NCL or NPM1 immunoprecipitates (Fig. 4F; see the long exposure image). As expected, the immunoprecipitation of one of the two nucleolar proteins coimmunoprecipitated with the other, even if the quantity of NPM1 coimmunoprecipitated with NCL and that of the latter coimmunoprecipitated with NPM1 were small (Fig. 4F). Inversely, because the relative quantity of FANCA is largely inferior to that of NCL or NPM1 (it is barely detectable when 5 μ g of total protein extract was used as input; Fig. 4, B to F), our results suggest that only a very low proportion of NCL or NPM1 eventually coimmunoprecipitates with FANCA, whereas a more substantial proportion of FANCA coimmunoprecipitates with NCL or NPM1.

In conclusion, our data revealed that FANCA participates in complex assembly of NPM1 and NCL, even if the relative weakness of the interaction, i.e., its absence in yeast two-hybrid analysis and its partial or total loss following exposure to an RNA/DNA nuclease or to high salt, advocates for an indirect association. Thus, our data suggest that FANCA could exist in two separate complexes or aggre-




Fig. 4. FANCA immunoprecipitates with NPM1 and NCL. (A) Anti-FANCA rabbit antibodies from Abcam, Bethyl, and Cell Signaling laboratories were used to immunoprecipitate FANCA in cell extracts from exponentially growing human lymphoblasts (HSC93), human bone osteosarcoma cells (U2OS), or human embryonic kidney cells (HEK293). Immunoblotting was performed with anti-FANCA Bethyl or Abcam antibodies and antibodies against FANCG, NCL, and NPM1. N.D., Not Done. (B) Immunoprecipitation (IP) with a FANCG antibody followed by immunoblot with antibodies against the indicated proteins. Different quantities of input fractions were analyzed to clearly visualize FANCA and FANCG. (C and D) Immunocomplexes isolated by the FANCA antibody were treated with benzonase [(C), two independent experiments], 150 nM NaCl, or 300 nM NaCl (D) before immunoblot analysis. Different quantities of input fractions were analyzed to clearly visualize FANCA and FANCG. (E) Immunoprecipitation with a FANCA antibody in cell extracts from HSC93 (WT), EGF070 (*FANCG*^{-/-}), and EGF004 (*FANCG*^{-/-}) cells followed by immunoblot with antibodies against the indicated proteins. Different quantities of input fractions were loaded. (F) NCL or NPM1 were immunoprecipitated from HEK293 or HSC93 cells. Immunoblot showing the coimmunoprecipitation of the indicated proteins when cell extracts were immunoprecipitated with anti-NCL or anti-NPM1 antibodies.

gates: one with FANCG and another with NPM1 and NCL, the first involved in DDR and the second associated with nucleolar homeostasis.

FANCA deficiency associates altered ribosome profiles with reduced protein synthesis

Ribosome biogenesis is the other main process that takes place in the nucleolus. We reasoned that FANCA loss of function altering

the nucleolar localization of proteins such as NCL and NPM1 could affect ribosome biogenesis and, consequently, the translation process, which, in turn, would amplify the nucleolar abnormalities observed in FANCA-depleted cells. Thus, to determine whether this was the case, we quantified nascent protein synthesis by measuring OP-Puro incorporation in FANCA^{-/-} (HSC72 and HSC99), FANCC^{-/-} (HSC536), and FANCG^{-/-} (EGF004 and EGF070) lymphoblasts as well as in FANCA pathway-proficient cells [the FANCA- and FANCC-corrected counterparts (HSC72CORR and HSC536CORR) and the WT HSC93 and GM3657 cell lines]. Flow cytometry analysis (fig. S3B) revealed a diminished OP-Puro signal indicative of a reduced rate of protein synthesis in FANCA- and FANCG-deficient cells (Fig. 5, A to C). Similar results were observed in FANCA-depleted versus FANCC-depleted, FANCD2-depleted, and FANCA pathway-proficient HeLa cells, indicating that the observed anomalies are essentially associated with the loss of function of the FANCA-FANCG subgroup of the FANCCore complex.

To further analyze the involvement of FANCA in protein synthesis, we performed polysome profiling, which allows a rough evaluation of translation process proficiency (44). Such analysis revealed a higher 80S monosome/polysome ratio in FANCA-deficient cells than in FANCA-proficient cells (Fig. 5D), indicative of a delay in translation initiation. Notably, the expression of WT complementary DNA (cDNA) in the patient-derived FANCA-deficient cell line completely recovered the observed abnormality. The level of FANCA expression in HSC72CORR cells was not beyond the level observed in FANCA-proficient cells (Fig. 5C). Thus, the observed polysome profile of the HSC72CORR cells perfectly overlays that of the FANCA pathway-proficient HSC93 cells, validating the rescuing of the FANCA activity associated with the efficiency of the translational machinery.

Next, we performed a liquid chromatography–tandem mass spectrometry (LC-MS/MS)–based analysis of the cytosolic, ribosomal, and polysomal fractions enriched in RPs and translational factors. MS and successive WB analysis identified FANCA as the sole FANCCore complex protein present in the cytosolic and ribosomal fractions (40S, 60S, and 80S) and revealed its absence in polysomes (Fig. 5E). Notably, among all the FANCA proteins, our MS analysis retrieved only FANCI and FANCD2, which were present in the 80S and polysomal fractions.

Next, we focused our analysis on the key components of the translational initiation process identified by MS, i.e., the RPs of the small and large subunits (RPS and RPL, respectively) and the eukaryotic translation initiation factors (eIFs). Globally, MS analysis in FANCA-deficient and FANCA-proficient cells identified all the known RPSs, RPLs, and eIFs. The analysis of the cytosols enriched in RPs and translational factors by MS demonstrated imbalances in the stoichiometry of several RPs and translation factors in each individual experiment, suggesting a requirement for FANCA for the optimal assembly of the translation machinery. Successively, for robustness, we looked for proteins retrieved in three of the four experiments on the cytosolic fractions or in both analyzed experiments performed on the 80S and polysomal fractions with an HSC72/HSC72corr ratio of >1.5 (higher level in FANCA^{-/-} cells) or <0.66 (higher level in WT-FANCA-corrected cells) (Fig. 5F). In the cytosolic fraction, the levels of RPS27A, RPL22L1, and RPL39 were substantially increased in FANCA-mutated cells. The level of RPL22L1 is also increased in the 80S monosomal fraction, which additionally presents a deficiency in RPL7L1. Last, in the cytosolic fraction, FANCA deficiency associates with an increased level of eIF4Y,




Fig. 5. FANCA deficiency leads to an altered ribosome profile and reduced protein synthesis. (A) Time-course incorporation of OP-Puro assessed by FACS in FANCA lymphoblasts (HSC72) and their corrected counterpart (HSC72CORR) cultured in 12 or 15% FCS. (B) Relative levels of OP-Puro incorporation in FANCA-proficient (HSC93 and GM3657), FANCA^{-/-} (HSC72 and HSC99), FANCC^{-/-} (HSC536), or FANCC-corrected lymphoblasts. Bars represent the mean of three to five independent experiments \pm SEM. The value observed in HSC93 cells was set to 1 in each individual experiment. Statistical significance was assessed with a two-tailed Student's *t* test against the GM03657 cell line ($*P < 0.05$ and $***P < 0.005$). (C) Western blot showing the expression of FANCA and FANCG in the indicated cell lines. (D) Polysome profiling in FANCA-deficient HSC72 and FANCA-proficient HSC72corr and HSC93 lymphoblasts and quantification of the polysome/monosome ratio in HSC72 relative to HSC72corr cells. Bars represent the mean of four independent experiments \pm SEM. The value of the HSC72corr cell was set to 1 in each individual experiment. (E) Western blots showing FANCA presence in the ribosomal-enriched cytoplasmic, 40S, 60S, and monosome (80S) fractions. (F) Histograms representing the mean expression level of the indicated proteins in the cytosol, 80S, and polysomes in FANCA-deficient cells compared with their corrected counterparts. Data are from MS analysis. (G) Western blots showing the expression of the indicated proteins in whole-cell (WCE) and ribosome-enriched (Tot. Rib.) extracts in HSC72 and HSC72CORR cells in four experiments. (H) Simplified diagram illustrating the several roles of FANCA in cell physiology.

eIF5A, and eIF6 and a deficit in both eIF4E2 and eIF4G1. In the 80S fraction from *FANCA*^{-/-} cells, several eukaryotic initiation factors, including eIF2B4, eIF3J, eIF4E, and eIF4G1, were underrepresented. In the polysomal fraction, only the level of eIF4G1 was altered between *FANCA*-deficient and *FANCA*-proficient cells, supporting the hypothesis that *FANCA* affects translation initiation efficiency but not progression. Therefore, despite undeniable variability, two factors appeared to be robustly affected by the absence of *FANCA*: RPL22L1, overrepresented in the cytosolic and 80S ribosomal enriched fractions, and eIF4G1, the only underrepresented in all the analyzed fractions. To validate the MS data, we analyzed RPL5, eIF4E2, and eIF6 expression in the same extracts by WB (Fig. 5G).

Together, the previous data provide two unexpected evidence. First, *FANCA*, unique among the FANCCore complex proteins, cosegregates with isolated ribosome subunits and with the 80S monosome associated with mRNA. Second, its loss of function perturbs the physiology of the ribosome and of the translational machinery, affecting the translation rate of the cells.

DISCUSSION

Our present work unveiled new phenotypic traits associated with the loss of function of *FANCA*, known to be responsible for 60 to 70% of FA cases worldwide. *FANCA*-deficient cells harbor several hallmarks of nucleolar stress, including delocalization of proteins from the nucleolus to the nucleus and the cytosol, impairment of ribosome biogenesis, and reduced translation efficiency (Fig. 5H). Supporting their dependence on *FANCA* inactivation, nucleolar and translational abnormalities were observed following siRNA-mediated depletion of *FANCA* in HeLa, U2OS, and HEK293 cells as well as in primary and immortalized cells issued from FA-A patients, where they are rescued by the ectopic expression of WT *FANCA*. We provided several robust pieces of evidence demonstrating that the observed nucleolar and translational abnormalities in *FANCA*-deficient cells represent the readout of new *FANCA*-associated function(s) on the cellular physiology and not an additional consequence of the canonical defects in DDR associated with the loss of function of the FANCCore pathway.

We showed here that the depletion of *FANCA*, which, like FANCC or FANCD2, is localized inside the nucleolus, has the same consequences on nucleolar DNA damage, rDNA instability, and R-loop accumulation observed following FANCD2 depletion. However, FANCC-, FANCG-, or FANCD2-depleted or mutant cells show lower levels of nucleolar stress than in the absence of *FANCA*. Moreover, *FANCA* depletion in *FANCC*^{-/-} or *FANCG*^{-/-} cell lines significantly increased the frequency of cells with nucleolar abnormalities. Thus, even if part of the observed nucleolar anomalies can effectively depend on the role of the FANCCore pathway in the DDR, our observations represent a first step in supporting the existence of a *FANCA* “private” role in the maintenance of nucleolar homeostasis.

Next, we demonstrated that *FANCA*, but not its partner FANCG, coimmunoprecipitates two of the major nucleolar proteins, NCL and NPM1, and that their coimmunoprecipitation is independent of FANCG or FANCC. Thus, together, the results of our immunoprecipitations revealed that *FANCA* associates with (at least) two separate and independent complexes: one with FANCG, known to be involved in DDR and participating in FANCD2/FANCI monoubiquitination and subnuclear foci assembly, and another with NCL and NPM1. Our data strengthen several observations demonstrating

specific roles of the individual FANCCore proteins and of *FANCA* in particular, regardless of their participation in the FANCCore pathway (13–15). Although two-thirds of FA patients present biallelic *FANCA* mutations, the activity of the protein is not mandatory for FANCD2 monoubiquitination and resistance to DNA damage (12, 13, 15), meaning that the BMF and the preleukemic status in such patients might be partially unrelated to altered DDR and the associated genetic instability.

The observed interaction of *FANCA* with NPM1 and the nuclear/cytoplasmic delocalization of NPM1 in *FANCA*-depleted cells are of particular interest. The nucleolar exclusion of NPM1 is a known consequence of somatic heterozygous mutations that abolish a nucleolar localization signal (45, 46) and/or create an additional nuclear exclusion signal (47) that sequesters the mutated protein, NPM1^c or NPM1^{mut}, in the cytoplasm, where it has been immunoprecipitated with *FANCA* (48), an interaction that fosters NPM1^c stability. The NPM1^c mutation is a key event observed in more than one-third of acute myeloid leukemia (AML) cases (49, 50). DNA damage induction in NPM1^c-mutated AML allows ATM-dependent nuclear/nucleolar import of the mutated protein (51). On the basis of previous work, we speculate that *FANCA*, whose activity in DDR is ATM/ATR signaling dependent (52, 53), contributes to the correct spatio-temporal localization and activity of NPM1 (and even NPM1^c) in different settings, and consequently, the observed mislocalization of NPM1 outside the nucleolus in *FANCA*-deficient cells could participate in both the BMF and the preleukemic status of FA patients.

Both NPM1 and NCL are abundant multifunctional proteins with roles in several unrelated cellular processes, including the DDR and DNA repair (54). Thus, *FANCA* behaves like a hub protein, mediating the trafficking/localization of several other proteins and complexes. In accordance with such a role as a hub protein, we unveiled the presence of *FANCA*, unique among the FANCCore complex proteins, in the cytosolic fraction enriched in ribosomal subunits, as well as in the 40S, 60S, and 80S fractions. A survey on the BioGRID database (<https://thebiogrid.org/>) revealed eight proteins as potential common interactors of *FANCA*, NCL, and NPM1, including the RP RPL18 that we retrieved in our immunoprecipitations with anti-*FANCA* antibody (preliminary observation; fig. S3C). Although *FANCA* depletion did not alter the stoichiometry of RPL18 in the analyzed ribosomal fractions in our MS analysis, *FANCA* deficiency was clearly associated with alterations in the composition of the ribosomal subunits and in translation. In particular, *FANCA* deficiency affects the levels of RPL22L1, eIF6, eIF4G1, and eIF4E, alterations that can participate or amplify the FA phenotypes. First, the RPL22L1/RPL22 balance is critical for HSC emergence and maintenance (55). Second, the observed increased association of eIF6 with the total ribosomal fraction and the reduced translation rate observed in *FANCA*-deficient cells are reminiscent of the phenotypic hallmarks of another rare BMF disease, SDS, resulting from downstream consequences of mutations in the *SBDS* or *EFL1* genes (56, 57). Third, the observed alterations in eIF4G1 and eIF4E levels could contribute to both the reduced translation rate and altered DDR in *FANCA*-deficient cells. eIF4G1 and eIF4E are key factors for mRNA scanning and AUG selection (58), rate-limiting steps in translational initiation that appeared altered in *FANCA*-depleted cells. As we observed in *FANCA*-deficient cells, eIF4G1 downregulation leads to a decrease in overall protein synthesis of approximately 20% (58, 59) and to an increased cellular sensitivity to DNA damage.

To underline its specificity in ribosome biogenesis and translation, FANCA was the sole FANCCore complex protein present in the fraction enriched in ribosomal subunits. A possibility is that its presence can be mediated by interactions with rRNAs and/or mRNAs. As also reported for FANCD2 (60), FANCA has been shown to have a stronger affinity for RNA and single-stranded DNA (ssDNA) than for double-stranded DNA (dsDNA), with a K_d (dissociation constant) significantly better for single-stranded RNA (ssRNA) (2.8 nM) than for ssDNA (11.1 nM) (43). The RNA binding activity of FANCA could be involved in nucleolar and/or ribosome biogenesis homeostasis, which we discovered as perturbed in its absence. More generally, in such fractions, among the more than 20 proteins associated with the FANCA pathway, we retrieved only FANCI and FANCD2.

The presence of FANCI in the ribosomal fractions validated previous data demonstrating that the functions of FANCI, such as FANCA, encompass ribosome biogenesis and DNA repair. As reported here for FANCA, Sondalle *et al.* (61) demonstrated that FANCI depletion perturbs rDNA transcription and processing slightly but consistently (in both cases, delayed formation of the mature forms was observed) and affects global translation. As in the current study, Sondalle *et al.* (61) reported that FANCD2 depletion did not perturb rDNA transcription, rRNA processing, or translation.

Last, we cannot ignore that the loss of function of FANCG, contrary to that observed in cells deficient in FANCC or FANCD2, leads to impaired translation (Fig. 5B) and, in some settings, affects the localization of nucleolar proteins more than a deficiency in FANCC or FANCD2 (Fig. 1, F and I). FANCG with FAAP20 forms a trimeric complex with FANCA, and depletion of FANCG strongly affects the expression of FANCG (Fig. 1, J and K). However, FANCG did not coimmunoprecipitate with NCL or NPM1, it was not identified as FANCA in the ribosomal fractions analyzed by MS, and, in its absence, FANCA still coimmunoprecipitated with NCL and NPM1 (Fig. 4F). Thus, we support the hypothesis that the observed consequences of FANCG deficiency on nucleolar and ribosomal homeostasis are due to its consequences on FANCA expression more likely than on its direct involvement in such processes.

In conclusion, our observations extend the phenotypic landscape associated with FANCA loss of function and drive FA closer to the group of iBMF syndromes called ribosomopathies that include DC, DBA, and SDS, in which BMF is associated with mutations in protein-coding genes for which the loss of function directly leads to alteration in nucleolar homeostasis and ribosome biogenesis, supporting the centrality of nucleolar metabolism in the maintenance of bone marrow functionality. Last, our observations unveil a key role for FANCA in two stress response pathways, the DDR and the NSR networks, whose activity is required for the steady-state maintenance of the BM and for raising proficient cancer barriers.

MATERIALS AND METHODS

Cell lines, culture, and reagents

Cell lines are listed in table S1. Adherent cells (HeLa, U2OS, HCT116, HEK293, and human and mouse fibroblasts) were grown in Dulbecco's modified Eagle's medium (DMEM) (Life Technologies) supplemented with 10% fetal calf serum (FCS), penicillin (0.5 mg/ml), streptomycin (100 µg/ml), and 1 mM pyruvate at 37°C and 5% CO₂. Human lymphoblasts were grown in RPMI medium (Life Technologies) supplemented with 12% FCS, penicillin (0.5 mg/ml),

and streptomycin (100 µg/ml) at 37°C and 5% CO₂. Cell cultures were regularly tested for the absence of mycoplasma.

ATM and/or ATR inhibitors, 1 mM caffeine (Sigma-Aldrich), 10 µM KU-55933 (Abcam), and 100 nM VE-822 (Sellchem) were added to the culture medium 6 hours after transfection. The addition was repeated every 24 hours until the end of the experiment.

siRNA and plasmid transfection

siRNA sequences are listed in table S2. siRNAs were transfected at 20 to 40 nM using calcium phosphate diluted at 6.25 mM in Hanks' Balanced Salt Solution (HBSP) buffer [750 µM Na₂HPO₄, 5 mM KCl, 140 mM NaCl, 25 mM Hepes (pH 7)] or with INTERFERin (Polyplus). The FANCA-YFP plasmid (a gift from K. J. Patel, Cambridge, UK) was transfected using jetPRIME (Polyplus) in HeLa cells or Fugene HD (Promega) in U2OS cells. A FANCA-Flag vector (a gift of A. Constantinou, CNRS, Montpellier, France) was transfected using jetPRIME (Polyplus) in HEK293 cells, and a stable expressing cell population was isolated under antibiotic selection.

Immunofluorescence and image quantification

Antibodies are listed in table S3. Samples were fixed 48 to 72 hours after siRNA transfection. For FBL, NCL, NPM1, and UBF, cells were washed with phosphate-buffered saline (PBS), fixed in 4% formaldehyde (Sigma-Aldrich) for 5 min at room temperature, and permeabilized in PBS with 0.5% Triton (Sigma-Aldrich) for 5 min at room temperature. For R-loops and G-quadruplexes, cells were washed with PBS, fixed in methanol at -20°C for 5 min, and then blocked in PBS, 0.05% Tween 20, and 3% bovine serum albumin for 1 hour at room temperature and stained with primary antibodies followed by secondary antibodies in the same buffer. Epifluorescence images were acquired with a Zeiss microscope at ×63 magnification 1.4 NA (numerical aperture). Quantification was performed on at least 100 cells. Nucleolar and nucleoplasmic intensity quantification of R-loops and G-quadruplexes was performed on epifluorescence images using CellProfiler software and FBL staining as a nucleolar marker. For colocalization assessment, image acquisition was performed using a confocal Leica TCS Sp8 microscope at ×63 magnification 1.4 NA (with magnification to a resolution of approximately 40 nm per pixel). Deconvolution was performed using Huygens software. A negative control was performed by acquiring each signal separately.

EM analysis

Ultrastructural study: Seventy-two hours after siRNA transfection, cell monolayers were fixed in 2% glutaraldehyde in 0.1 M Sörensen phosphate buffer for 1 hour at 4°C. The cells were scraped off during fixation and centrifuged. The fixed pellets were rinsed for 1 hour in ice-cold phosphate buffer, postfixed with 2% aqueous osmium tetroxide, and dehydrated in increasing concentrations of ethanol before Epon embedding. Polymerization was carried out for 48 hours at 60°C. Ultrathin sections were stained with standard uranyl acetate and lead citrate before observation with an FEI Tecnai Spirit transmission electron microscope at 80 kV. Digital images were taken with a SIS MegaView III charge-coupled device (CCD) camera.

Protein extraction, immunoprecipitation, and Western blotting

Antibodies are listed in table S3. Cellular extracts for immunoprecipitation were prepared from exponentially growing lymphoblasts or adherent cells. Cells were lysed on ice for 30 min in NaCl, EDTA,

Tris, NP-40 (NETN) buffer [150 mM/300 mM NaCl, 50 mM tris (pH 8.0), 1% NP-40, 1 mM EDTA] supplemented with phosphatase inhibitor PhosSTOP (Roche) and cOmplete ULTRA EDTA-Free Protease inhibitors (Roche). Cells were sonicated for 2×10 s at 30% (Vibracell 75042, Bioblock) and spun down for 5 min at 13,000 rpm. Supernatants were quantified using the Bradford assay (BioPhotometer, Eppendorf). One milligram of protein extract was used per immunoprecipitation. For each immunoprecipitation, antibodies (3 μ g) were coupled to 20 μ l of magnetic beads (Dynabeads Protein G Magnetic Beads, Thermo Fisher Scientific). Beads washed in $1 \times$ PBS (two times) were resuspended in 300 μ l of $1 \times$ PBS and incubated with antibodies for at least 2 hours in a roll shaker in a cold room. To preclear the protein extracts, 10 μ l of beads washed in PBS and in NETN buffer was added to each whole protein extract in the presence of 0.5 μ g of control immunoglobulin G (IgG) and incubated for at least 2 hours in a roll shaker in a cold room. Beads coupled with IgG were collected on a magnetic support and discarded. Supernatants were resuspended in beads coupled to specific antibodies. A small amount of the precleared protein extract was kept as input. Precleared supernatants were incubated with the magnetic beads coupled to the antibodies overnight in a roll shaker in a cold room. When necessary, cells were incubated for 10 min at room temperature after the addition of benzonase (Merck, 1 mM) and 1 mM $MgCl_2$ to the lysate. Beads coupled with antibodies were captured on a magnetic support and washed four times with NETN buffer before being resuspended in 40 μ l of $2 \times$ Laemmli and heated for 5 min at 70°C to dissociate proteins and antibodies from the beads. The supernatants were transferred into a new tube, 1 μ l of μ -mercaptoethanol was added, and half of this immunoprecipitation was loaded on an acrylamide gel after 5 min of heating at 98°C. For analysis of protein expression, cells were lysed in 50 mM tris-HCl (pH 7.5), 125 mM NaCl, 1 mM $MgCl_2$, and 0.1% SDS buffer supplemented with benzonase (Merck, 1:1000), phosphatase inhibitor PhosSTOP (Roche), and cOmplete ULTRA EDTA-Free Protease inhibitors (Roche). Proteins were resuspended in Laemmli's blue [16 mM tris-HCl (pH 6.8), 10% glycerol, 2.5% SDS] supplemented with β -mercaptoethanol (Sigma-Aldrich, 1:10). Proteins from immunoprecipitation and cellular extracts were separated by electrophoretic migration performed in 2.5 mM tris, 19.2 mM glycine, and 0.01% SDS buffer. Semidry transfer was performed with a TransBlot cell apparatus (Bio-Rad) in transfer buffer composed of 2.5 mM tris-HCl (pH 8.3), 19.2 mM glycine, 0.01% SDS, and 20% isopropanol for 1 hour and 30 min at 20 V. Liquid transfer was performed in an XCell II module (Invitrogen) in 2.5 mM tris-HCl (pH 8.3), 19.2 mM glycine, 0.04% SDS, and 20% methanol buffer at 15 V overnight at 4°C. Nitrocellulose membranes (Protran 0.2 mm, Amersham) were blocked for at least 1 hour in 0.1% PBS-Tween 20 and 5% milk and incubated with primary antibodies in PBS/0.1% Tween 20/5% milk. Visualization was performed using ECL (Life), Western Bright ECL (Advansta), West Dura ECL, or West Femto ECL (Thermo Fisher Scientific) developer. Images were acquired using a CCD camera (General Electric) or Amersham Imager 600 (GE Healthcare).

PCR-based analysis of rDNA rearrangement

Seventy-two hours after transfection, cells were lysed, and DNA was extracted using the Maxwell RSC Blood DNA Kit (Promega). PCR was performed on 100 ng of DNA using Phusion polymerase (0.02 U/ml), 0.2 mM deoxynucleotide triphosphate (dNTP), and 0.5 mM of the following probes: forward: 5'-AGTCGGGTTGCTTGGAATGC-3';

reverse: 5'-GGACAAACCCTTGTGTGCGAGG-3' (predicted position in gene: nucleotides 8204 to 12970). The following amplification program was used: 98°C, 30 s; $35 \times$ (98°C, 10 s; 62°C, 30 s; 72°C, 4 min); 72°C, 10 min.

Metabolic labeling

Seventy-two hours after siRNA transfection, nonconfluent HeLa cells were incubated for 1 hour at 37°C and 5% CO_2 in phosphate-free DMEM containing 10% dialyzed FCS. They were then pulsed for 20 min with 15 mCi of [^{32}P]orthophosphate (PerkinElmer). After two washes in culture medium, they were incubated for a chase period of 1 to 6 hours. RNA was extracted using TRIzol reagent, and 1 mg of RNA was loaded on a denaturing gel with Ethidium Bromide (EtBr). The EtBr signal was acquired after migration. The gel was dried, and the radioactive signal was acquired using a Typhoon FLA9500 scanner (GE Healthcare). Signals were quantified using Fiji software.

Northern blot

Seventy-two hours after siRNA transfection, 1 mg of TRIzol-extracted RNA was loaded on a denaturing gel with BET. RNA was passively transferred on a nitrocellulose membrane (Amersham) in SSC $10 \times$ buffer [1.5 M NaCl, 0.15 M sodium citrate (pH 7)]. The BET signal was acquired after transfer. Membranes were blocked in $3 \times$ SSC, $5 \times$ Denhardt's, 0.5% SDS, and transfer RNA (tRNA) (0.5 mg/ml) for 1 hour at 45°C. Northern blot probes (described in table S4) were labeled with 25 mCi of [^{32}P]ATP (adenosine triphosphate) (PerkinElmer) using T4 polynucleotide kinase (NEB). Incubation was performed overnight at 45°C. Radioactive signals were acquired using a Typhoon FLA9500 scanner (GE Healthcare).

EU and OP-Puro labeling

EU (BaseClick) and *O*-propyl-puromycin (Jena Bioscience) were from the same kit using 5-FAM (Lumiprobe) as a fluorophore. Seventy-two hours after transfection, labeling was performed by adding EU (1 mM) for 15 min and OP-Puro (50 mM) for 15 to 45 min. Labeling was analyzed by flow cytometry (C6, BD Accuri apparatus).

Chromatin immunoprecipitation

HeLa cells (10×10^6 to 15×10^6) were grown in petri dishes (confluency of approximately 70 to 80%). Forty-eight hours after transfection, the medium was replaced with fresh medium, and fixation was performed as recommended by the ChIP-IT High Sensitivity Kit (Active Motif) (15 min in 1.1% paraformaldehyde fixation). Cells were then processed using the ChIP-IT High Sensitivity Kit, and immunoprecipitation was performed using 4 μ g of the antibodies listed in table S3.

Chromatin immunoprecipitation-quantitative PCR

Probes are listed in table S5. For rDNA ChIP-qPCR, the following program was used: 50°C, 2 min; 95°C, 10 min; $45 \times$ (95°C, 15 s; 58°C, 1 min/30 s); dissociation stage (95°C, 15 s; 60°C, 1 min; 95°C, 15 s; 60°C, 15 s).

Enriched ribosome fraction isolation

Cells were lysed in 20 mM tris (pH 7.4), 150 mM NaCl, 5 mM $MgCl_2$, 1 mM dithiothreitol (DTT), cycloheximide (100 μ g/ml), and 1% Triton and triturated 10 times through a 26-gauge needle. The lysate was clarified by centrifugation at 10 min for 20,000g at 4°C, and the supernatant was loaded on a 1 M sucrose cushion prepared

in 20 mM tris (pH 7.4), 150 mM NaCl, 5 mM MgCl₂, 1 mM DTT, and cycloheximide (100 µg/ml). Ribosomes were recovered after centrifugation at 4 hours for 70,000 rpm at 4°C in a TLA100.3 rotor (Beckman) and washed in PBS followed by 1 hour at 70,000 rpm at 4°C (62).

Polysomal fractionation

Cycloheximide (100 µg/ml) was added for 5 min to cell cultures and maintained in PBS washes. Cells were fractionated in 5 mM tris (pH 7.5), 2.5 mM MgCl₂, and 1.5 mM KCl buffer supplemented with cOMplete ULTRA EDTA-free protease inhibitors (Roche), cycloheximide (100 µg/ml), RNase inhibitor (Promega RNasin 0.2 U/µl), 2 mM DTT, 0.5% Triton, and 0.5% sodium deoxycholate, and nuclei were discarded after a 7-min 16,000g centrifugation. The cytoplasmic optical density (OD) at 260 nm was assessed, and the lysate was diluted up to 10 to 20 OD (40 OD for MS). Then, 500 µl was loaded on a 5 to 50% sucrose gradient [20 mM Hepes (pH 7.6), 100 mM KCl, 5 mM MgCl₂, 10 µM cycloheximide, ¹/₁₀ protease inhibitors, and RNase inhibitor (10 U/ml)] and centrifuged for 2 hours at 36,000 rpm at 4°C in a Beckman SW41Ti rotor. The A₂₅₄ of the fractions was determined using a UA-6 UV/VIS detector (63).

LC-MS/MS acquisition

Protein extracts (30 µg) were precipitated with acetone at -20°C for 3 hours and incubated with 20 µl of 25 mM NH₄HCO₃ containing sequencing-grade trypsin (12.5 µg/ml; Promega) overnight at 37°C. The resulting peptides were desalted using ZipTip µ-C18 Pipette Tips (Millipore) and analyzed in technical triplicates by a Q-Exactive Plus coupled to a Nano-LC Proxeon 1000 equipped with an easy spray ion source (all from Thermo Fisher Scientific). Peptides were separated by chromatography with the following parameters: Acclaim PepMap100 C18 precolumn (2 cm, 75 µm inside diameter, 3 µm, 100 Å), Pepmap-RSLC Proxeon C18 column (50 cm, 75 µm inside diameter, 2 µm, 100 Å), flow rate (300 nl/min), gradient from 95% solvent A (water, 0.1% formic acid) to 35% solvent B (100% acetonitrile, 0.1% formic acid) over a period of 98 min, followed by column regeneration for 23 min, giving a total run time of 2 hours. Peptides were analyzed in the Orbitrap cell, in full ion scan mode, at a resolution of 70,000 [at mass/charge ratio (*m/z*) 200], with a mass range of *m/z* 375 to 1500 and an automatic gain control (AGC) target of 3 × 10⁶. Fragments were obtained by high collision-induced dissociation activation with a collisional energy of 30% and a quadrupole isolation window of 1.4 Da. MS/MS data were acquired in the Orbitrap cell in Top20 mode at a resolution of 17,500, with an AGC target of 2 × 10⁵, and a dynamic exclusion of 30 s. MS/MS of most intense precursors was first acquired. Peptides with unassigned charge states or monocharged peptides were excluded from the MS/MS acquisition. The maximum ion accumulation times were set to 50 ms for MS acquisition and 45 ms for MS/MS acquisition.

Quantitative analysis of protein abundance variations

Label-free relative quantification was performed in between subject analysis for each biological independent experiment, condition by condition, with raw data acquired in technical replicates, using Progenesis-Qi software 3.0 (Nonlinear Dynamics Ltd., Newcastle, UK). The procedure was as follows: (i) chromatogram alignment, (ii) peptide abundance normalization, which was performed on a set of 76 RPs, (iii) statistical analyses of features, and (iv) peptide identification. For this last step, all MS and MS/MS data were processed

with Proteome Discoverer software (Thermo Fisher Scientific, version 2.1) and with the Mascot search engine (Matrix Science, version 5.1). The mass tolerance was set to 7 ppm for precursor ions and 0.02 Da for fragments. The maximum number of missed cleavages was limited to two for the trypsin protease. The following variable modifications were allowed: oxidation (Met) and phosphorylation (Ser and Thr). The SwissProt database (02/17) with the *Homo sapiens* taxonomy was used for the MS/MS identification step. Peptide identifications were validated using a 1% false discovery rate threshold calculated with the Percolator algorithm. Abundance variation measured for each protein by label-free quantification was validated if the calculated analysis of variance (ANOVA) *P* values were <0.05.

SUPPLEMENTARY MATERIALS

Supplementary material for this article is available at <http://advances.sciencemag.org/cgi/content/full/7/1/eabb5414/DC1>

[View/request a protocol for this paper from Bio-protocol.](#)

REFERENCES AND NOTES

1. M. Tsekrekou, K. Stratigi, G. Chatzinikolaou, The nucleolus: In genome maintenance and repair. *Int. J. Mol. Sci.* **18**, 1411 (2017).
2. S. Boulon, B. J. Westman, S. Hutten, F.-M. Boisvert, A. I. Lamond, The nucleolus under stress. *Mol. Cell* **40**, 216–227 (2010).
3. J. M. Liu, S. R. Ellis, Ribosomes and marrow failure: Coincidental association or molecular paradigm? *Blood* **107**, 4583–4588 (2006).
4. D. Ruggero, A. Shimamura, Marrow failure: A window into ribosome biology. *Blood* **124**, 2784–2792 (2014).
5. M. Boglioli, J. Surrallés, Fanconi anemia: A model disease for studies on human genetics and advanced therapeutics. *Curr. Opin. Genet. Dev.* **33**, 32–40 (2015).
6. R. Ceccaldi, P. Sarangi, A. D. D'Andrea, The Fanconi anaemia pathway: New players and new functions. *Nat. Rev. Mol. Cell Biol.* **17**, 337–349 (2016).
7. A. Gueiderikh, F. Rosselli, J. B. C. Neto, A never-ending story: The steadily growing family of the FA and FA-like genes. *Genet. Mol. Biol.* **40**, 398–407 (2017).
8. R. Ceccaldi, K. Parmar, E. Mouly, M. Delord, J. M. Kim, M. Regairaz, M. Pla, N. Vasquez, Q. S. Zhang, C. Ponderre, R. Peffault de Latour, E. Gluckman, M. Cavazzana-Calvo, T. Leblanc, J. Larghero, M. Grompe, G. Socie, A. D. D'Andrea, J. Soulier, Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. *Cell Stem Cell* **11**, 36–49 (2012).
9. D. Walter, A. Lier, A. Geiselhart, F. B. Thalheimer, S. Huntscha, M. C. Sobotta, B. Moehle, D. Brocks, I. Bayindir, P. Kaschutnig, K. Muedder, C. Klein, A. Jauch, T. Schroeder, H. Geiger, T. P. Dick, T. Holland-Letz, P. Schmezer, S. W. Lane, M. A. Rieger, M. A. G. Essers, D. A. Williams, A. Trumpp, M. D. Milsom, Exit from dormancy provokes DNA-damage-induced attrition in haematopoietic stem cells. *Nature* **520**, 549–552 (2015).
10. I. V. Rosado, F. Langevin, G. P. Crossan, M. Takata, K. J. Patel, Formaldehyde catabolism is essential in cells deficient for the Fanconi anemia DNA-repair pathway. *Nat. Struct. Mol. Biol.* **18**, 1432–1434 (2011).
11. F. Langevin, G. P. Crossan, I. V. Rosado, M. J. Arends, K. J. Patel, Fancd2 counteracts the toxic effects of naturally produced aldehydes in mice. *Nature* **475**, 53–58 (2011).
12. S. van Twest, V. J. Murphy, C. Hodson, W. Tan, P. Swuec, J. J. O'Rourke, J. Heierhorst, W. Crismani, A. J. Deans, Mechanism of ubiquitination and deubiquitination in the Fanconi anemia pathway. *Mol. Cell* **65**, 247–259 (2017).
13. D. Adachi, T. Oda, H. Yagasaki, K. Nakasato, T. Taniguchi, A. D. D'Andrea, S. Asano, T. Yamashita, Heterogeneous activation of the Fanconi anemia pathway by patient-derived FANCA mutants. *Hum. Mol. Genet.* **11**, 3125–3134 (2002).
14. M. Nepal, C. Ma, G. Xie, W. Jia, P. Fei, Fanconi anemia complementation group C protein in metabolic disorders. *Aging* **10**, 1506–1522 (2018).
15. A. Benitez, W. Liu, A. Palovcak, G. Wang, J. Moon, K. An, A. Kim, K. Zheng, Y. Zhang, F. Bai, A. V. Mazin, X. H. Pei, F. Yuan, Y. Zhang, FANCA promotes DNA double-strand break repair by catalyzing single-strand annealing and strand exchange. *Mol. Cell* **71**, 621–628.e4 (2018).
16. T. Kaddar, M. Carreau, Fanconi anemia proteins and their interacting partners: A molecular puzzle. *Anemia* **2012**, 425814 (2012).
17. D. Briot, G. Mace-Aime, F. Subra, F. Rosselli, Aberrant activation of stress-response pathways leads to TNF-alpha oversecretion in Fanconi anemia. *Blood* **111**, 1913–1923 (2008).
18. F. Rosselli, J. Sanceau, E. Gluckman, J. Wietzerbin, E. Moustacchi, Abnormal lymphokine production: A novel feature of the genetic disease Fanconi anemia. II. In vitro and in vivo spontaneous overproduction of tumor necrosis factor alpha. *Blood* **83**, 1216–1225 (1994).

19. A. Oppezio, J. Bourseguin, E. Renaud, P. Pawlikowska, F. Rosselli, Microphthalmia transcription factor expression contributes to bone marrow failure in Fanconi anemia. *J. Clin. Invest.* **130**, 1377–1391 (2020).
20. H. Zhang, D. E. Kozono, K. W. O'Connor, S. Vidal-Cardenas, A. Rousseau, A. Hamilton, L. Moreau, E. F. Gaudiano, J. Greenberger, G. Bagby, J. Soulier, M. Grompe, K. Parmar, A. D. D'Andrea, TGF-beta inhibition rescues hematopoietic stem cell defects and bone marrow failure in Fanconi anemia. *Cell Stem Cell* **18**, 668–681 (2016).
21. A. Epanchintsev, P. Shyamsunder, R. S. Verma, A. Lyakhovich, IL-6, IL-8, MMP-2, MMP-9 are overexpressed in Fanconi anemia cells through a NF-kappaB/TNF-alpha dependent mechanism. *Mol. Carcinog.* **54**, 1686–1699 (2015).
22. N. Matsushita, Y. Endo, K. Sato, H. Kurumizaka, T. Yamashita, M. Takata, S. Yanagi, Direct inhibition of TNF-alpha promoter activity by Fanconi anemia protein FANCD2. *PLOS ONE* **6**, e23324 (2011).
23. R. Zanier, D. Briot, J. A. Dugas du Villard, A. Sarasin, F. Rosselli, Fanconi anemia C gene product regulates expression of genes involved in differentiation and inflammation. *Oncogene* **23**, 5004–5013 (2004).
24. M. Moriel-Carretero, S. Ovejero, M. Gerus-Durand, D. Vryzas, A. Constantinou, Fanconi anemia FANCD2 and FANCI proteins regulate the nuclear dynamics of splicing factors. *J. Cell Biol.* **216**, 4007–4026 (2017).
25. W. Du, Z. Adam, R. Rani, X. Zhang, Q. Pang, Oxidative stress in Fanconi anemia hematopoiesis and disease progression. *Antioxid. Redox Signal.* **10**, 1909–1921 (2008).
26. G. Pagano, A. A. Talamanca, G. Castello, M. d'Ischia, F. V. Pallardo, S. Petrovic, B. Porto, L. Tian, A. Zatterale, From clinical description, to in vitro and animal studies, and backward to patients: Oxidative stress and mitochondrial dysfunction in Fanconi anemia. *Free Radic. Biol. Med.* **58**, 118–125 (2013).
27. G. Pagano, P. Degan, M. d'Ischia, F. J. Kelly, B. Nobili, F. V. Pallardo, H. Youssoufian, A. Zatterale, Oxidative stress as a multiple effector in Fanconi anaemia clinical phenotype. *Eur. J. Haematol.* **75**, 93–100 (2005).
28. R. A. Schwab, J. Nieminszczy, F. Shah, J. Langton, D. Lopez Martinez, C. C. Liang, M. A. Cohn, R. J. Gibbons, A. J. Deans, W. Niedzwiedz, The Fanconi anemia pathway maintains genome stability by coordinating replication and transcription. *Mol. Cell* **60**, 351–361 (2015).
29. M. Kruhlak, E. E. Crouch, M. Orlov, C. Montano, S. A. Gorski, A. Nussenzweig, T. Misteli, R. D. Phair, R. Casellas, The ATM repair pathway inhibits RNA polymerase I transcription in response to chromosome breaks. *Nature* **447**, 730–734 (2007).
30. M. van Sluis, B. McStay, A localized nucleolar DNA damage response facilitates recruitment of the homology-directed repair machinery independent of cell cycle stage. *Genes Dev.* **29**, 1151–1163 (2015).
31. G. R. Kidiyoor, A. Kumar, M. Foiani, ATR-mediated regulation of nuclear and cellular plasticity. *DNA Repair* **44**, 143–150 (2016).
32. D. O. Warmerdam, J. van den Berg, R. H. Medema, Breaks in the 45S rDNA lead to recombination-mediated loss of repeats. *Cell Rep.* **14**, 2519–2527 (2016).
33. H. Ma, T. Pederson, The nucleolus stress response is coupled to an ATR-Chk1-mediated G2 arrest. *Mol. Biol. Cell* **24**, 1334–1342 (2013).
34. R. D. Kennedy, C. C. Chen, P. Stuckert, E. M. Archila, M. A. De la Vega, L. A. Moreau, A. Shimamura, A. D. D'Andrea, Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. *J. Clin. Invest.* **117**, 1440–1449 (2007).
35. J. H. Guervilly, G. Mace-Aime, F. Rosselli, Loss of CHK1 function impedes DNA damage-induced FANCD2 monoubiquitination but normalizes the abnormal G2 arrest in Fanconi anemia. *Hum. Mol. Genet.* **17**, 679–689 (2008).
36. M. L. Garcia-Rubio, C. Perez-Calero, S. I. Barroso, E. Tumini, E. Herrera-Moyano, I. V. Rosado, A. Aguilera, The Fanconi anemia pathway protects genome integrity from R-loops. *PLOS Genet.* **11**, e1005674 (2015).
37. C. Y. Jao, A. Salic, Exploring RNA transcription and turnover in vivo by using click chemistry. *Proc. Natl. Acad. Sci. U.S.A.* **105**, 15779–15784 (2008).
38. A. Cammas, S. Millevoi, RNA G-quadruplexes: Emerging mechanisms in disease. *Nucleic Acids Res.* **45**, 1584–1595 (2017).
39. D. Rhodes, H. J. Lipps, G-quadruplexes and their regulatory roles in biology. *Nucleic Acids Res.* **43**, 8627–8637 (2015).
40. P. Richard, J. L. Manley, R Loops and links to human disease. *J. Mol. Biol.* **429**, 3168–3180 (2016).
41. J. M. Santos-Pereira, A. Aguilera, R loops: New modulators of genome dynamics and function. *Nat. Rev. Genet.* **16**, 583–597 (2015).
42. A. C. Hall, L. A. Ostrowski, V. Pietrobon, K. Mekhail, Repetitive DNA loci and their modulation by the non-canonical nucleic acid structures R-loops and G-quadruplexes. *Nucleus* **8**, 162–181 (2017).
43. F. Yuan, L. Qian, X. Zhao, J. Y. Liu, L. Song, G. D'Urso, C. Jain, Y. Zhang, Fanconi anemia complementation group A (FANCA) protein has intrinsic affinity for nucleic acids with preference for single-stranded forms. *J. Biol. Chem.* **287**, 4800–4807 (2012).
44. H. Chasse, S. Boulben, V. Costache, P. Cormier, J. Morales, Analysis of translation using polysome profiling. *Nucleic Acids Res.* **45**, e15 (2017).
45. B. Falini, N. Bolli, A. Liso, M. P. Martelli, R. Mannucci, S. Pileri, I. Nicoletti, Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: Molecular basis and clinical implications. *Leukemia* **23**, 1731–1743 (2009).
46. B. Falini, N. Bolli, J. Shan, M. P. Martelli, A. Liso, A. Pucciarini, B. Bigerna, L. Pasqualucci, R. Mannucci, R. Rosati, P. Gorello, D. Diverio, G. Roti, E. Tiacci, G. Cazzaniga, A. Biondi, S. Schnittger, T. Haferlach, W. Hiddemann, M. F. Martelli, W. Gu, C. Mecucci, I. Nicoletti, Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. *Blood* **107**, 4514–4523 (2006).
47. N. Bolli, I. Nicoletti, M. F. De Marco, B. Bigerna, A. Pucciarini, R. Mannucci, M. P. Martelli, A. Liso, C. Mecucci, F. Fabbiano, M. F. Martelli, B. R. Henderson, B. Falini, Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants. *Cancer Res.* **67**, 6230–6237 (2007).
48. W. Du, J. Li, J. Sipple, J. Chen, Q. Pang, Cytoplasmic FANCA-FANCC complex interacts and stabilizes the cytoplasm-dislocalized leukemic nucleophosmin protein (NPMc). *J. Biol. Chem.* **285**, 37436–37444 (2010).
49. B. Falini, C. Mecucci, E. Tiacci, M. Alcalay, R. Rosati, L. Pasqualucci, R. La Starza, D. Diverio, E. Colombo, A. Santucci, B. Bigerna, R. Pacini, A. Pucciarini, A. Liso, M. Vignetti, P. Fazi, N. Meani, V. Pettirossi, G. Saglio, F. Mandelli, F. Lo-Coco, P. G. Pellicci, M. F. Martelli; GIMEMA Acute Leukemia Working Party, Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. *N. Engl. J. Med.* **352**, 254–266 (2005).
50. N. Meani, M. Alcalay, Role of nucleophosmin in acute myeloid leukemia. *Expert Rev. Anticancer Ther.* **9**, 1283–1294 (2009).
51. G. D. Bailey, H. M. H. Qutob, A. Akhtar, N. H. Russell, C. H. Seedhouse, DNA damage corrects the aberrant cytoplasmic localisation of nucleophosmin in NPM1 mutated acute myeloid leukaemia. *Br. J. Haematol.* **186**, 343–347 (2019).
52. N. B. Collins, J. B. Wilson, T. Bush, A. Thomashevski, K. J. Roberts, N. J. Jones, G. M. Kupfer, ATR-dependent phosphorylation of FANCA on serine 1449 after DNA damage is important for FA pathway function. *Blood* **113**, 2181–2190 (2009).
53. T. Taniguchi, I. Garcia-Higuera, B. Xu, P. R. Andreassen, R. C. Gregory, S. T. Kim, W. S. Lane, M. B. Kastan, A. D. D'Andrea, Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways. *Cell* **109**, 459–472 (2002).
54. D. D. Scott, M. Oeffinger, Nucleolin and nucleophosmin: Nuclear proteins with multiple functions in DNA repair. *Biochem. Cell Biol.* **94**, 419–432 (2016).
55. Y. Zhang, A. C. Duc, S. Rao, X. L. Sun, A. N. Billbee, M. Rhodes, Q. Li, D. J. Kappes, J. Rhodes, D. L. Wiest, Control of hematopoietic stem cell emergence by antagonistic functions of ribosomal protein paralogs. *Dev. Cell* **24**, 411–425 (2013).
56. A. J. Finch, C. Hilcenko, N. Basse, L. F. Drynan, B. Goyenechea, T. F. Menne, A. Gonzalez Fernandez, P. Simpson, C. S. D'Santos, M. J. Arends, J. Donadieu, C. Bellanne-Chantelot, M. Costanzo, C. Boone, A. N. McKenzie, S. M. Freund, A. J. Warren, Uncoupling of GTP hydrolysis from eIF6 release on the ribosome causes Shwachman-Diamond syndrome. *Genes Dev.* **25**, 917–929 (2011).
57. S. Tan, L. Kermasson, A. Hoslin, P. Jaako, A. Faille, A. Acevedo-Arozena, E. Lengline, D. Ranta, M. Poiree, O. Fenneteau, H. Ducou le Pointe, S. Fumagalli, B. Beaupain, P. Nitschke, C. Bole-Feynot, J. P. de Villartay, C. Bellanne-Chantelot, J. Donadieu, C. Kannengiesser, A. J. Warren, P. Revy, EFL1 mutations impair eIF6 release to cause Shwachman-Diamond syndrome. *Blood* **134**, 277–290 (2019).
58. O. Haimov, U. Sehrawat, A. Tamarkin-Ben Harush, A. Bahat, A. Uzonyi, A. Will, H. Hiraishi, K. Asano, R. Dikstein, Dynamic interaction of eukaryotic initiation factor 4G1 (eIF4G1) with eIF4E and eIF1 underlies scanning-dependent and -independent translation. *Mol. Cell Biol.* **38**, e00139-18 (2018).
59. M. Badura, S. Braunstein, J. Zavadil, R. J. Schneider, DNA damage and eIF4G1 in breast cancer cells reprogram translation for survival and DNA repair mRNAs. *Proc. Natl. Acad. Sci. U.S.A.* **109**, 18767–18772 (2012).
60. Z. Liang, F. Liang, Y. Teng, X. Chen, J. Liu, S. Longerich, T. Rao, A. M. Green, N. B. Collins, Y. Xiong, L. Lan, P. Sung, G. M. Kupfer, Binding of FANCI-FANCD2 complex to RNA and R-loops stimulates Robust FANCD2 monoubiquitination. *Cell Rep.* **26**, 564–572.e5 (2019).
61. S. B. Sondalle, S. Longerich, L. M. Ogawa, P. Sung, S. J. Baserga, Fanconi anemia protein FANCI functions in ribosome biogenesis. *Proc. Natl. Acad. Sci. U.S.A.* **116**, 2561–2570 (2019).
62. N. T. Ingolia, G. A. Brar, S. Rouskin, A. M. McGeachy, J. S. Weissman, The ribosome profiling strategy for monitoring translation in vivo by deep sequencing of ribosome-protected mRNA fragments. *Nat. Protoc.* **7**, 1534–1550 (2012).
63. V. Gandin, K. Sikstrom, T. Alain, M. Morita, S. McLaughlan, O. Larsson, I. Topisirovic, Polysome fractionation and analysis of mammalian translomes on a genome-wide scale. *J. Vis. Exp.* **17**, 51455 (2014).
64. C. Grandori, N. Gomez-Roman, Z. A. Felton-Edkins, C. Ngouenet, D. A. Galloway, R. N. Eisenman, R. J. White, c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. *Nat. Cell Biol.* **7**, 311–318 (2005).

Acknowledgments: We thank all the members of the UMR9019-CNRS research unit for helpful discussions; the Proteomics platform of the Jacques Monod Institute (UMR7592 CNRS/Paris Diderot University) for the quantitative proteomics experiments; the Imaging and Cytometry Platform, UMS 23/3655, Gustave Roussy Cancer Campus, University Paris Saclay, Villejuif, France; P. Pasero for the gift of the S9.6 hybridoma-purified antibody and for sharing protocols; K. J. Patel and A. Constantinou for the gift of the FANCA-YFP and Flag-FANCA vectors, respectively; the Fanconi Anemia Research Fund (FARF) for the gift of antibodies; and A. Londono for the gift of the G4 antibody. **Funding:** A.G. was a fellow of the INSERM School Liliane Bettencourt and was supported by a "Course of Excellence in Oncology—Fondation Philanthropia" award. This work was funded by a grant from La Ligue Contre Le Cancer to F.R. **Author contributions:** A.G., F.M.-C., G.R., and S.S.-B. performed experiments. A.G. and F.R. conceived and designed experiments. S.A. and J.-J.D. provided expertise on nucleolar metabolism and ribosome biogenesis. A.G., S.A., J.-J.D., and F.R. analyzed the data. A.G. and F.R. wrote the paper. F.R. financed the study. Figure contributions: A.G.: Figs. 1, A to D and

F; 2, A and C to F; 3, B to G; and 5, A, B, and D to G; F.M.-C.: Figs. 1, I to K; 4, A to F; and 5C; G.R.: Figs. 2, B and F, and 3G; S.S.-B.: Fig. 1E. **Competing interests:** The authors declare that they have no competing interest. **Data and materials availability:** All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.

Submitted 3 March 2020

Accepted 28 October 2020

Published 1 January 2021

10.1126/sciadv.abb5414

Citation: A. Gueiderikh, F. Maczkowiak-Chartois, G. Rouvet, S. Souquère-Besse, S. Apcher, J.-J. Diaz, F. Rosselli, Fanconi anemia A protein participates in nucleolar homeostasis maintenance and ribosome biogenesis. *Sci. Adv.* **7**, eabb5414 (2021).

Fanconi anemia A protein participates in nucleolar homeostasis maintenance and ribosome biogenesis

Anna Gueiderikh, Frédérique Maczkowiak-Chartois, Guillaume Rouvet, Sylvie Souquère-Besse, Sébastien Apcher, Jean-Jacques Diaz and Filippo Rosselli

Sci Adv 7 (1), eabb5414.
DOI: 10.1126/sciadv.abb5414

ARTICLE TOOLS

<http://advances.sciencemag.org/content/7/1/eabb5414>

SUPPLEMENTARY MATERIALS

<http://advances.sciencemag.org/content/suppl/2020/12/21/7.1.eabb5414.DC1>

REFERENCES

This article cites 64 articles, 18 of which you can access for free
<http://advances.sciencemag.org/content/7/1/eabb5414#BIBL>

PERMISSIONS

<http://www.sciencemag.org/help/reprints-and-permissions>

Use of this article is subject to the [Terms of Service](#)

Science Advances (ISSN 2375-2548) is published by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. The title *Science Advances* is a registered trademark of AAAS.

Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).